148 related articles for article (PubMed ID: 36094435)
1. Role of syndecan-4 in breast cancer pathophysiology.
Onyeisi JOS; Lopes CC; Götte M
Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1345-C1354. PubMed ID: 36094435
[TBL] [Abstract][Full Text] [Related]
2. microRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4.
Onyeisi JOS; Greve B; Espinoza-Sánchez NA; Kiesel L; Lopes CC; Götte M
J Cell Biochem; 2021 Oct; 122(10):1491-1505. PubMed ID: 34180077
[TBL] [Abstract][Full Text] [Related]
3. Cell surface heparan sulfate proteoglycans control adhesion and invasion of breast carcinoma cells.
Lim HC; Multhaupt HA; Couchman JR
Mol Cancer; 2015 Jan; 14(1):15. PubMed ID: 25623282
[TBL] [Abstract][Full Text] [Related]
4. Syndecan-1 (CD138) as a Pathogenesis Factor and Therapeutic Target in Breast Cancer.
Sheta M; Götte M
Curr Med Chem; 2021; 28(25):5066-5083. PubMed ID: 34191695
[TBL] [Abstract][Full Text] [Related]
5. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
6. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.
Watanabe A; Mabuchi T; Satoh E; Furuya K; Zhang L; Maeda S; Naganuma H
J Neurooncol; 2006 Mar; 77(1):25-32. PubMed ID: 16132527
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer.
Onyeisi JOS; Lopes CC; Götte M
Biomolecules; 2021 Mar; 11(4):. PubMed ID: 33810567
[TBL] [Abstract][Full Text] [Related]
8. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation.
Subramanian SV; Fitzgerald ML; Bernfield M
J Biol Chem; 1997 Jun; 272(23):14713-20. PubMed ID: 9169435
[TBL] [Abstract][Full Text] [Related]
9. Mapping of matrix metalloproteinase cleavage sites on syndecan-1 and syndecan-4 ectodomains.
Manon-Jensen T; Multhaupt HA; Couchman JR
FEBS J; 2013 May; 280(10):2320-31. PubMed ID: 23384311
[TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 modulates β-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
Hassan H; Greve B; Pavao MS; Kiesel L; Ibrahim SA; Götte M
FEBS J; 2013 May; 280(10):2216-27. PubMed ID: 23289672
[TBL] [Abstract][Full Text] [Related]
11. Syndecan-3 and perlecan are differentially expressed by progenitors and mature oligodendrocytes and accumulate in the extracellular matrix.
Winkler S; Stahl RC; Carey DJ; Bansal R
J Neurosci Res; 2002 Aug; 69(4):477-87. PubMed ID: 12210841
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate chains of syndecan-1 regulate ectodomain shedding.
Ramani VC; Pruett PS; Thompson CA; DeLucas LD; Sanderson RD
J Biol Chem; 2012 Mar; 287(13):9952-9961. PubMed ID: 22298773
[TBL] [Abstract][Full Text] [Related]
13. Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart.
Strand ME; Herum KM; Rana ZA; Skrbic B; Askevold ET; Dahl CP; Vistnes M; Hasic A; Kvaløy H; Sjaastad I; Carlson CR; Tønnessen T; Gullestad L; Christensen G; Lunde IG
FEBS J; 2013 May; 280(10):2228-47. PubMed ID: 23374111
[TBL] [Abstract][Full Text] [Related]
14. Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells.
Beauvais DM; Rapraeger AC
Exp Cell Res; 2003 Jun; 286(2):219-32. PubMed ID: 12749851
[TBL] [Abstract][Full Text] [Related]
15. Heparan Sulfate Proteoglycans in Human Colorectal Cancer.
Vicente CM; da Silva DA; Sartorio PV; Silva TD; Saad SS; Nader HB; Forones NM; Toma L
Anal Cell Pathol (Amst); 2018; 2018():8389595. PubMed ID: 30027065
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma.
Lendorf ME; Manon-Jensen T; Kronqvist P; Multhaupt HA; Couchman JR
J Histochem Cytochem; 2011 Jun; 59(6):615-29. PubMed ID: 21430259
[TBL] [Abstract][Full Text] [Related]
17. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.
Davies EJ; Blackhall FH; Shanks JH; David G; McGown AT; Swindell R; Slade RJ; Martin-Hirsch P; Gallagher JT; Jayson GC
Clin Cancer Res; 2004 Aug; 10(15):5178-86. PubMed ID: 15297422
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-1 signals independently of beta1 integrins during Raji cell spreading.
Lebakken CS; McQuade KJ; Rapraeger AC
Exp Cell Res; 2000 Sep; 259(2):315-25. PubMed ID: 10964499
[TBL] [Abstract][Full Text] [Related]
19. Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.
Ding K; Lopez-Burks M; Sánchez-Duran JA; Korc M; Lander AD
J Cell Biol; 2005 Nov; 171(4):729-38. PubMed ID: 16286510
[TBL] [Abstract][Full Text] [Related]
20. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
